ANDAORALTABLET
Approved
Nov 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PITAVASTATIN CALCIUM (pitavastatin calcium) by Evergreen Therapeutics is 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase, the enzyme that catalyzes the conversion of hmg-coa to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. First approved in 2023.
Drug data last refreshed 18h ago
$0.0BPart D
Mechanism of Action
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Evergreen Therapeutics
Worked on PITAVASTATIN CALCIUM at Evergreen Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.